EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...